Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• More detailed data from the June 2026 analysis are intended to be presented at an upcoming medical meeting.

  60% confidence

• The study demonstrated a statistically significant benefit in the primary analysis for progression-free survival (PFS), one of the study's two primary endpoints along with OS.

  60% confidence

• A hazard ratio of 0.76 was observed in both the full intention-to-treat population and the subgroup of western patients as of the June 2026 data cut-off.

  60% confidence

• Ivonescimab plus platinum-doublet chemotherapy continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone.

  60% confidence

Cited in these Via News reports

• Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not →